A 19-year-old woman with polyarthritis, anterior uveitis and coronary vasculitis: A case of adult Kawasaki disease

D’Angelo, Fabrizia; Varisco, Pierre Alain; So, Alexander; Taponnier, Maxime; Zufferey, Pascal

doi:10.1016/j.jbspin.2014.10.021

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We describe an adolescent patient with KD in temporal association with the administration of the first dose of the COVID-19 mRNA vaccine BNT162b2. The diagnostic elements of KD consisted of the characteristic mucocutaneous signs, anterior uveitis, 10 11 and development of persistent coronary dilatation. The patient's age and the occurrence of cholestatic hepatopathy were consistent with the diagnosis of adult-onset KD rather than classic childhood KD.…”

Section: Discussionmentioning

confidence: 99%

A Case of Adult-Onset Kawasaki Disease in an Adolescent Occurring during the COVID-19 Pandemic

Aebi

Schöbi

Duppenthaler

et al. 2022

J Pediatr Infect Dis

View full text Add to dashboard Cite

We report the occurrence of the adult-onset type of Kawasaki disease (KD) with classic mucocutaneous manifestations of KD, cholestatic liver disease, multiple splenic infarcts, and residual multiple coronary artery dilatations in a previously healthy 14-year-old male adolescent 16 days after having received one dose of the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine. First, the report serves to highlight the diagnostic challenges of adult-onset KD often resulting in therapeutic delay and the frequently reported occurrence of persistent cardiovascular sequelae. Second, the report emphasizes that the temporal association of KD with the administration of a COVID-19 vaccine will likely be a frequent constellation in the near future, raising questions of a causative association. While there is currently no evidence of such an association in persons above 5 years of age, large-scale vaccination of children below 5 years of age will require close surveillance of vaccine-related adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%